INCIDENCE OF SHINGLES

The incidence of shingles in immunocompromised adults aged ≥18 years exceeds that of immunocompetent adults aged ≥50 years1 

Adults who are immunocompromised due to disease or therapy have an increased risk for herpes zoster (HZ).1,2

Incidence rates in immunocompromised patients aged ≥18 years ranged between 9 and 96 HZ cases/1000 person-years and were highest in individuals with hematopoietic stem cell transplant, followed by those with hematologic malignancy, solid organ transplant, solid tumor malignancy, and HIV.1,*

Herpes Zoster Incidence Rates in Immunocompromised Adults vs Immunocompetent Adults Aged ≥50 Years
Graph of Incidence of Herpes Zoster in Immunocompromised Adults

*Data from a systematic review involving individuals ≥18 years of age with hematopoietic stem cell transplant, hematologic malignancies, solid tumors, HIV, or solid organ transplants.1

 

The risk of herpes zoster may also be increased in patients with systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis, who may be immunocompromised due to underlying disease or therapy, with incidence rates ranging between 8 to 15/1000 person-years.3

 

BM=bone marrow transplant; HIV=human immunodeficiency virus; HM=hematologic malignancies; PY=person-years; SCT=stem cell transplant; SOT=solid organ transplant; ST=solid tumors.

You may also be interested in:

Efficacy

Learn about efficacy data in immunocompromised patients aged 18 years and older.

SEE DATA

Safety Profile

Learn about the safety profile of SHINGRIX in immunocompromised patients aged 18 years and older.

SAFETY INFO

Storage & Dosing

Learn how to store and properly dose SHINGRIX.

SEE HOW

Indication & Important Safety Info

Indication

Important Safety Information

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)  
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)  
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or
1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. McKay SL, Guo A, Pergam S, Dooling K. Clin Infect Dis. 2020;71(7):e125-e134.
  2. Centers for Disease Control and Prevention. Shingles (herpes zoster): clinical overview. Reviewed June 27, 2024. Accessed October 25, 2024. https://www.cdc.gov/shingles/hcp/clinical-overview/index.html
  3. Chen SY, Suaya JA, Li Q, et al. Infection. 2014;42(2):325-334.
  4. Bastidas A, de la Serna J, El ldrissi M, et al. JAMA. 2019;322(2):123-133.
  5. Winston DJ, Mullane KM, Cornely OA, et al. Lancet. 2018;391(10135):2116-2127.
  6. Sahoo F, Hill JA, Xie H, et al. Bio Blood Marrow Transplant. 2017;23(3):505-511.
  7. Zhang D, Weiss T, Feng Y, Finelli L. Adv Ther. 2017;34(7):1610-1621.
  8. Dagnew AF, llhan O, Lee WS, et al. Lancet Infect Dis. 2019;19(9):988-1000.
  9. Habel LA, Ray GT, Silverberg MJ, et al. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82-90.
  10.  Koo S, Gagne LS, Lee P, et al. Transpl Infect Dis. 2014;16(1):17-25.
  11.  Pergam SA, Forsberg CW, Boeckh MJ, et al. Transpl Infect Dis. 2011;13(1):15-23.
  12.  Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Transpl Infect Dis. 2008;10(4):260-268.
  13.  Mao J, McPheeters JT, Finelli L. Medicine (Baltimore). 2017;96(48):e8746.
  14.  Tseng HF, Tartof S, Harpaz R, et al. Clin Infect Dis. 2014;59(7):913-919.
  15.  Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. J Acquir Immune Defic Syndr. 2012;61(2):203-207.
  16.  Prosser LA, Harpaz R, Rose AM, et al. Ann Intern Med. 2019;170(60)(suppl):1-32.

    Questions About SHINGRIX?

    Call: 1-800-772-9292

    Available Monday - Friday

    8:30 am to 5:30 pm ET